Ironwood Pharmaceuticals, Inc. $IRWD Stock Holdings Trimmed by Renaissance Technologies LLC

Renaissance Technologies LLC lowered its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 1.8% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,061,073 shares of the biotechnology company’s stock after selling 143,900 shares during the quarter. Renaissance Technologies LLC owned about 4.94% of Ironwood Pharmaceuticals worth $28,294,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of IRWD. Krilogy Financial LLC grew its position in shares of Ironwood Pharmaceuticals by 9.8% in the 1st quarter. Krilogy Financial LLC now owns 33,194 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 2,971 shares in the last quarter. ProShare Advisors LLC increased its holdings in shares of Ironwood Pharmaceuticals by 9.6% in the 4th quarter. ProShare Advisors LLC now owns 36,315 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 3,170 shares during the last quarter. Integrated Wealth Concepts LLC raised its position in shares of Ironwood Pharmaceuticals by 21.4% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 3,406 shares in the last quarter. DGS Capital Management LLC raised its position in shares of Ironwood Pharmaceuticals by 42.8% during the 1st quarter. DGS Capital Management LLC now owns 14,883 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 4,458 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV lifted its stake in Ironwood Pharmaceuticals by 7.8% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 76,951 shares of the biotechnology company’s stock worth $259,000 after purchasing an additional 5,598 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have commented on IRWD shares. Zacks Research raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 1st. Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a report on Friday. Finally, Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Sunday, May 17th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $6.23.

Insiders Place Their Bets

In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 127,890 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total value of $578,062.80. Following the sale, the insider directly owned 313,680 shares in the company, valued at approximately $1,417,833.60. This trade represents a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Julie Mchugh sold 21,571 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total transaction of $80,459.83. Following the transaction, the director directly owned 250,749 shares of the company’s stock, valued at approximately $935,293.77. This trade represents a 7.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 9.30% of the stock is owned by corporate insiders.

Ironwood Pharmaceuticals Stock Down 2.8%

Shares of IRWD stock opened at $3.80 on Wednesday. The company has a market cap of $619.63 million, a P/E ratio of 6.33 and a beta of 0.20. The business has a 50 day moving average of $3.85 and a two-hundred day moving average of $3.98. Ironwood Pharmaceuticals, Inc. has a 52 week low of $0.71 and a 52 week high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $106.51 million for the quarter, compared to analyst estimates of $92.11 million. Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%. Analysts expect that Ironwood Pharmaceuticals, Inc. will post 1.04 EPS for the current fiscal year.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.